Immunology’s Next 10 Years: Trends 2025–2035

Prediction 1: Individualized mRNA cancer vaccines approved in 2–3 cancer types (Confidence: HIGH)

Based on mRNA-4157's Phase 2 data in melanoma adjuvant treatment (44% recurrence risk reduction), Moderna and Merck's Phase 3 trial is underway, with data expected in 2026–2027, FDA approval possible in 2027–2028. If melanoma Phase 3 data maintains Phase 2 levels, BioNTech's pancreatic cancer individualized vaccine (BNT122) Phase 2 results will also accelerate similar product development. By 2035, individualized mRNA vaccines may become standard adjuvant treatment in two to four high-mutation-burden cancers (melanoma, some lung cancer, high MSI colorectal cancer). For patients and families: high-risk post-surgical cancer patients will have a 'precision weapon' exclusively targeting their tumor's mutations, significantly reducing recurrence risk.

Prediction 2: Universal CAR-NK (Off-the-Shelf) approved (Confidence: HIGH)

MD Anderson's CAR-NK (allogeneic NK cells) 2020 NEJM data, and multiple companies' (Fate Therapeutics, Nkarta, Artiva, etc.) rapid clinical advancement, make universal CAR-NK one of the fastest-advancing areas in cell therapy. Expected in 2027–2030, at least one universal CAR-NK product will be approved in specific blood tumors (CD19+ lymphoma or AML), becoming the first truly 'off-the-shelf' cell therapy. Costs compared to autologous CAR-T reduced seventy to eighty percent, waiting time from weeks to days or less, greatly expanding cell therapy accessibility.

Prediction 3: CAR-T/CAR-NK approved for refractory autoimmune diseases (Confidence: MEDIUM-HIGH)

In 2021–2024, University of Erlangen Germany's Georg Schett team, using CD19-CAR-T to clear pathogenic B cells in patients with refractory SLE, myasthenia gravis, neuromyelitis optica spectrum disorder, and other refractory autoimmune diseases, achieved stunning results — over eighty percent of patients achieved deep remission, with some maintaining remission without subsequent immunosuppressants after stopping treatment. This is one of immunotherapy's most important breakthroughs in autoimmune disease, changing the traditional understanding of 'autoimmune disease can only be managed lifelong.' Expected 2026–2028, formal clinical trial data in this direction will change these diseases' treatment guidelines.

Prediction 4: In vivo CAR-T enters human clinical trials (Confidence: MEDIUM)

Mitchell's team (Penn) validated LNP in vivo T cell targeting in mice in 2022. From mice to humans typically requires three to five years of safety validation and preclinical work. Expected 2027–2030, the first in vivo CAR-T human Phase 1 safety trial begins (possibly in specific blood tumors or cardiac fibrosis indications). If Phase 1 safety data is positive, by 2032–2035, in vivo CAR-T clinical proof may begin forming — this will be cell therapy's true accessibility revolution.

Prediction 5: AI-assisted immunotherapy decision-making becomes oncology center routine (Confidence: HIGH)

AI's capacity in multi-omics integration and treatment response prediction has already shown predictive accuracy superior to traditional biomarkers in research environments. In the next ten years, as medical data standardizes and regulatory frameworks establish, AI-assisted tumor immune decision support systems (like MSK-IMPACT extended versions) will become standard procedures at top oncology centers, gradually expanding to regional hospitals. AI won't replace oncologists, but will become every oncologist's indispensable 'second assistant' — processing multidimensional patient data that human cognition can't integrate, providing optimal plan recommendations based on global hundreds of millions of patient cases.

Prediction 6: mRNA vaccine platform expands to flu, RSV (Confidence: HIGH)

This prediction has already been half realized: mRNA flu vaccine (Moderna's mRNA-1010) has shown superior antibody response levels compared to traditional egg-culture flu vaccines in 2023–2024 clinical trials, with FDA approval possible in 2025–2026. mRNA RSV vaccine (targeting elderly, an important pathogen) is similarly in late-stage clinical trials. By 2030, mRNA vaccine platform will cover flu, RSV, HPV (partially), and at least one cancer indication, becoming the most multifunctional, fastest-adaptable vaccine platform in human vaccine history — including being able to have vaccines available within six months when the next global pandemic pathogen appears, rather than traditional eighteen to twenty-four months.

Prediction 7: Senolytics enter at least one approved clinical indication (Confidence: MEDIUM-HIGH)

Idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD) are current Senolytic clinical trial most mature indications, with multiple Phase 2 randomized controlled trials underway. If D+Q or similar combination Phase 2 data is positive, Phase 3 trials will rapidly launch. Expected 2028–2032, Senolytics will gain first clinical approval in IPF or CKD, opening the era of 'senescent cell clearance' as a formal medical intervention.

Prediction 8: Spatial immunology enters clinical pathology diagnosis (Confidence: MEDIUM-HIGH)

Spatial transcriptomics in tumor microenvironment analysis has already produced clinically meaningful findings (Tertiary Lymphoid Structures correlate with prognosis). Multiplex protein spatial imaging (CODEX) is currently used as high-end research tools at some leading oncology centers. By 2030, these technologies' costs will decrease to nodes sufficient for key treatment decision use. By 2035, spatial immune analysis may become part of pathology reports for some cancers.

Prediction 9: NK cell therapy in cancer prevention/immune rejuvenation forms standardized application framework (Confidence: MEDIUM)

Currently NK cell therapy has considerable clinical data in blood tumor treatment. Over the next ten years, with further epidemiological validation of NK cell activity and cancer risk relationships, and accumulation of NK cell therapy safety data, there will emerge: a standardized clinical assessment and intervention pathway NK cell therapy application framework for middle-aged and elderly people with clearly declining NK activity and elevated cancer risk; NK cell activity testing incorporated into standard cancer risk assessment for high-risk populations; NK cell therapy combined with lifestyle interventions (exercise programs) as standardized options in comprehensive immune rejuvenation.

Prediction 10: BCG trained immunity forms international clinical guidelines (Confidence: MEDIUM)

ACTIVATE trial and multiple related studies have proven BCG's non-specific protective effects in elderly people. If the expected expanded ACTIVATE trial (larger sample, longer follow-up) publishes data in 2025–2028 and validates this effect, it may push WHO and multiple national immunization advisory committees to add 'trained immunity' indications for elderly people in BCG national vaccination plans — this would be the first time the 'innate immune training' concept is formally written into public health policy.